Abstract Number: L01 • ACR Convergence 2020
Outcomes of COVID-19 Infection in Patients with Rheumatic Diseases in a Multicenter Healthcare System: A Comparative Cohort Study
Background/Purpose: The risk of poor outcomes from COVID-19 among rheumatic disease patients compared to the general population remains poorly understood. Filling this knowledge gap is…Abstract Number: 0022 • ACR Convergence 2020
Association Between Changes in Pain Sensitization and Changes in Disease Activity After 12 Weeks of Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) have abnormalities in central nervous system regulation of pain, leading to enhanced pain sensitivity at joint sites (peripheral sensitization)…Abstract Number: 0576 • ACR Convergence 2020
Medical Savings of Timely Rheumatoid Arthritis Diagnoses
Background/Purpose: Previous studies suggest that early rheumatoid arthritis (RA) recognition and treatment provides greater clinical benefits than treatment started later in the disease course. However,…Abstract Number: 1015 • ACR Convergence 2020
The Prevalence and Risk Factors for Liver Fibrosis Among Rheumatoid Arthritis (RA) Patients on Disease-Modifying Anti-rheumatic Drugs (DMARDs)
Background/Purpose: Majority of DMARDs, including methotrexate (MTX), leflunomide (LEF) and sulfasalazine (SSZ) arebelieved to be hepatotoxic, causing liver fibrosis. However, the clinical findings were inconsistent.…Abstract Number: 1343 • ACR Convergence 2020
Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). It was approved in the US in December 2017 for…Abstract Number: 1874 • ACR Convergence 2020
Differences Between Men and Women in the Patient Pathways to Diagnosis of Ankylosing Spondylitis
Background/Purpose: Healthcare claims databases can be used to identify patients with ankylosing spondylitis (AS) prior to diagnosis. This study explores differences in pathways to AS…Abstract Number: 0089 • ACR Convergence 2020
The Risk Factors of Recurrence in Relapsing Polychondritis; A Study of 41 Cases
Background/Purpose: Relapsing polychondritis (RP) is a rare disease which causes inflammation in systemic cartilages. Although glucocorticoids (GC) and immunosuppressive drugs (IS) have been used, the…Abstract Number: 0584 • ACR Convergence 2020
Total Cost of Care for Patients with Rheumatoid Arthritis
Background/Purpose: The range of medical costs associated with rheumatoid arthritis (RA) is, in part, related to the various treatment options. Treatment for RA focuses on…Abstract Number: 1037 • ACR Convergence 2020
Relationship Between Air Quality and Sarcoidosis Inflammatory Activity
Background/Purpose: African Americans [AA] and minorities in the lower socioeconomic strata of Chicago are disproportionately affected by pulmonary sarcoidosis, and regularly exposed to poorer air…Abstract Number: 1464 • ACR Convergence 2020
Multi-Variate Approach Including Serology and Genetics for an Improved Identification of Patients at Risk of Developing Rheumatoid Arthritis
Background/Purpose: First-degree relatives of RA patients (FDR-RA) have an increased prevalence for rheumatoid arthritis (RA) [1] and joint symptoms [2]. Identification of individuals with imminent RA…Abstract Number: 1892 • ACR Convergence 2020
Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for F Ankylosing Spondylitis (AS) Patients with the App of Smart System of Disease Management (SSDM): A Cohort Study from China
Background/Purpose: Ankylosing Spondylitis Disease Activity Score (ASDAS) is adopted to evaluate the degree of disease activity and the inflammatory response in AS patients. ASDAS score…Abstract Number: 0178 • ACR Convergence 2020
Associations of Multimorbidity with DMARD Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness (RISE) Registry
Background/Purpose: Although a treat-to-target strategy is endorsed in rheumatoid arthritis (RA) treatment guidelines, its routine implementation in real-world settings, particularly in the context of multimorbidity,…Abstract Number: 0623 • ACR Convergence 2020
Cytokine Storm: Outcomes in SARS-CoV-2 Patients Treated with Biologics in a Rheumatology Cohort
Background/Purpose: Cytokine Release Syndrome (CRS) or Macrophage Activation Syndrome (MAS) is a life threating hyperinflammatory condition that can complicate rheumatic disease as well as infections…Abstract Number: 1082 • ACR Convergence 2020
The Presence of Anti-Jo1, anti-PL7, And/or anti-MDA5 Antibodies in Idiopathic Inflammatory Myopathy Confers an Increased Risk of a Significant Restrictive Pulmonary Defect
Background/Purpose: A subset of patients with idiopathic inflammatory myopathy develop significant restrictive lung disease, although risk factors for this are poorly defined. Autoantibodies may be…Abstract Number: 1492 • ACR Convergence 2020
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Report of Primary Study Outcomes
Background/Purpose: There is uncertainty regarding when to start biologic medications for polyarticular juvenile idiopathic arthritis (P-JIA). The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed…
- 1
- 2
- 3
- …
- 5
- Next Page »